Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer: AIM-HIGH (Adjuvant Intervention in Molecular High Risk Patients)

Inclusion Criteria: * Written informed consent * Age ≥ 18 years * Able to comply with the protocol, including acceptable candidacy for adjuvant chemotherapy according to local institutional standards and likely compliance with follow-up for anticipated length of study (i.e. 5 years from the initiation of enrollment). * Willing to be randomized to chemotherapy. * Histologically documented completely resected (R0) Stage I or IIA non-squamous NSCLC (per 8th edition, TNM staging system) * Adequate tissue sample for the 14-Gene Prognostic Assay * Life expectancy excluding NSCLC diagnosis ≥ 5 years * ECOG performance status 0-1 Exclusion Criteria: * Final pathologic diagnosis of pure squamous cell, pure small cell, or pure neuroendocrine histology, or any combination of only these three histologies * Evidence of greater than stage IIA pathologic staging * Evidence of incomplete resection * Pregnant or lactating women * Unwilling to use an effective means of contraception * Active infection, either systemic or at site of primary resection * Systemic chemotherapy or anti-cancer agent within 5 years prior to enrollment * Radiotherapy to the chest in the immediate pre- or post- operative period * Malignancies other than the current NSCLC within 5 years prior to randomization, except for adequately treated CIS of the cervix, non-melanoma skin cancer, localized prostate cancer treated locally, ductal carcinoma in situ treated surgically * Treatment with any investigational drug or participation in another clinical trial within 28 days prior to enrollment * Known hypersensitivity to study treatment agents * Evidence of any other disease including infection that contraindicates the use of systemic cytotoxic chemotherapy or puts the patient at high risk for treatment-related complications * Wound dehiscence or infection